Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-28
2005-06-28
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S530000, C548S540000
Reexamination Certificate
active
06911467
ABSTRACT:
Compounds which are 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives according to general formula (1) are DP-IV inhibitors for treatment of impaired glucose tolerance or type 2 diabetes; wherein A is selected from groups (2, 3 and 4); X is selected from aminoacyl groups corresponding to the natural amino acids, acyl groups R3CO, groups R4COOC(R5)(R6)OCO, methoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl; R1is selected from H, C1-C6alkyl residues, (CH2)aNHW1, (CH2)bCOW2, (CH2)cOW3, CH(Me)OW4, (CH2)d—C6H4—W5and (CH2)eSW6, where a is 2-5, b is 1-4, c is 1-2, d is 1-2, e is 1-3, W1is COW6, CO2W6or SO2W6, W2is OH, NH2, OW6or NHW6, W3is H or W6, W4is H or W6, W5is H, OH or OMe, and W6is C1-C6alkyl, optionally substituted phenyl, optionally substituted heteroaryl or benzyl and R2is selected from H and (CH2)n—C5H3N—Y, where n is 2-4 and Y is H, F, Cl, NO2or CN, or R1and R2together are —(CH2)p— where p is 3 or 4; R3is selected from H, C1-C6alkyl and phenyl; R4is selected from H, C1-C6alkyl, benzyl and optionally substituted phenyl; R5and R6are each independently selected from H and C1-C6alkyl or together are —(CH2)m—, where m is 4-6; R7is selected from pyridyl and optionally substituted phenyl; R8is selected from H and C1-C3alkyl; and R9is selected from H, C1-C6alkyl, C1-C6alkoxy and phenyl.
REFERENCES:
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6166063 (2000-12-01), Villhauer
patent: 6172081 (2001-01-01), Damon
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6319902 (2001-11-01), Sugawara et al.
patent: WO 95/15309 (1995-06-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 00/55125 (2000-09-01), None
patent: WO 00/56296 (2000-09-01), None
patent: WO 00/56297 (2000-09-01), None
Thomas E. Hughes et al., “NVP-DPP728 (1-[[[2-[(5-Cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyan (S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV”, Biochemistry, 1999, pp. 11597-11603, vol. 38, No. 36, XP000983860.
Takashi Yamada et al., “Studies of Unusual Amino Acids and Their Peptides. VIII The Syntheses of an Iminohexapeptide as a Model of Bottromycin and its Related Iminopeptides”, Bull. Chem. Soc. JPN. 1977, pp. 1827-1830, vol. 50, No. 7, XP000983920.
Takashi Yamada et al., “Studies of Unusual Amino Acids and Their Peptides. IX. The Synthetic Study of Bottromycins B1 and B2”, Bull. Chem. Soc. JPN. 1978, pp. 878-883, vol. 51, No. 3, XP000983921.
D M Ashworth et al., “2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chemistry Letters, 1996, pp. 1163-1166, vol. 6, No. 10, XP004124889, Oxford, GB.
Ferring BV
Foley & Lardner LLP
Shameem Golam M M
LandOfFree
Antidiabetic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antidiabetic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antidiabetic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3470467